Ascendis Pharma (ASND) is the lead sponsor of 10 active clinical trials listed on ClinicalTrials.gov[4], including 2 Phase 3[1], 6 Phase 2[2], 1 Phase 1[3].
Trial NCT05929807[5] evaluates TransCon CNP in Achondroplasia with a target enrollment of 140 participants. Trial NCT07221851[6] evaluates Lonapegsomatropin [SKYTROFA®] in Turner Syndrome with a target enrollment of 186 participants.
No Form 4 insider filings for ASND were recorded at the SEC in the past 30 days[7].